Abbott Laboratories (NYSE:ABT) Institutional Investors Sentiment Index Up in Q2 2019

Abbott Laboratories (NYSE:ABT) Logo

Sentiment for Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) institutional sentiment increased to 0.89 in Q2 2019. Its up 0.07, from 0.82 in 2019Q1. The ratio is positive, as 563 institutional investors increased and started new holdings, while 635 sold and reduced positions in Abbott Laboratories. The institutional investors in our partner’s database now own: 1.26 billion shares, down from 1.26 billion shares in 2019Q1. Also, the number of institutional investors holding Abbott Laboratories in their top 10 holdings decreased from 103 to 100 for a decrease of 3. Sold All: 46 Reduced: 589 Increased: 443 New Position: 120.

Abbott Laboratories manufactures and sells health care products worldwide. The company has market cap of $148.92 billion. The companyÂ’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; cardiovascular and metabolic products; and influenza vaccines, as well as to regulate physiological rhythm of the colon. It has a 51.82 P/E ratio. The Company’s Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic tests; informatics and automation solutions; and a suite of informatics tools and professional services.

The stock decreased 1.11% or $0.95 during the last trading session, reaching $84.26. About 2.29 million shares traded. Abbott Laboratories (NYSE:ABT) has risen 33.65% since September 13, 2018 and is uptrending. It has outperformed by 33.65% the S&P500.

Analysts await Abbott Laboratories (NYSE:ABT) to report earnings on October, 16. They expect $0.84 EPS, up 12.00 % or $0.09 from last year’s $0.75 per share. ABT’s profit will be $1.48B for 25.08 P/E if the $0.84 EPS becomes a reality. After $0.82 actual EPS reported by Abbott Laboratories for the previous quarter, Wall Street now forecasts 2.44 % EPS growth.

Brandywine Trust Co holds 9.34% of its portfolio in Abbott Laboratories for 157,149 shares. Sector Gamma As owns 687,260 shares or 9.29% of their US portfolio. Moreover, Green Valley Investors Llc has 7.73% invested in the company for 1.62 million shares. The Iowa-based United Fire Group Inc has invested 6.41% in the stock. Inspirion Wealth Advisors Llc, a Illinois-based fund reported 172,897 shares.

Abbott Laboratories (NYSE:ABT) Ratings Coverage

Ratings analysis reveals 100% of Abbott Labs’s analysts are positive. Out of 4 Wall Street analysts rating Abbott Labs, 4 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $86 while the high is $9400. The stock’s average target of $91.40 is 8.47% above today’s ($84.26) share price. ABT was included in 11 notes of analysts from March 14, 2019. Morgan Stanley maintained Abbott Laboratories (NYSE:ABT) on Tuesday, July 16 with “Overweight” rating. Wells Fargo maintained it with “Outperform” rating and $9100 target in Thursday, June 13 report. The firm has “Buy” rating by Cowen & Co given on Thursday, March 14. The stock of Abbott Laboratories (NYSE:ABT) has “Outperform” rating given on Thursday, July 18 by Raymond James. The stock of Abbott Laboratories (NYSE:ABT) has “Outperform” rating given on Thursday, July 18 by BMO Capital Markets.

More notable recent Abbott Laboratories (NYSE:ABT) news were published by: Finance.Yahoo.com which released: “Can We See Significant Institutional Ownership On The Abbott Laboratories (NYSE:ABT) Share Register? – Yahoo Finance” on August 05, 2019, also Finance.Yahoo.com with their article: “Is Abbott Laboratories (NYSE:ABT) Investing Your Capital Efficiently? – Yahoo Finance” published on July 02, 2019, Seekingalpha.com published: “University of California sues Abbott over probiotic – Seeking Alpha” on August 30, 2019. More interesting news about Abbott Laboratories (NYSE:ABT) were released by: Finance.Yahoo.com and their article: “Pharma Stock Calls Could Double Fast – Yahoo Finance” published on September 11, 2019 as well as Seekingalpha.com‘s news article titled: “Abbott launches study of TriClip for tricuspid regurgitation – Seeking Alpha” with publication date: September 05, 2019.

Abbott Laboratories (NYSE:ABT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.